Brief: Obseva And Yuyuan Bioscience Technology Submit Pre-Ind Dossier For Nolasiban With Chinese NMPA
01/07/2020 06:03
July 1 (Reuters) - Obseva SA OBSN.S :
* OBSEVA AND YUYUAN BIOSCIENCE TECHNOLOGY ANNOUNCE
SUBMISSION OF
PRE-IND DOSSIER FOR NOLASIBAN WITH CHINESE NMPA
* YUYUAN HAS SUBMITTED A PRE-IND MEETING REQUEST FOR
NOLASIBAN TO
CENTER FOR DRUG EVALUATION AT CHINESE NATIONAL MEDICAL PRODUCTS
ADMINISTRATION (NMPA)
Source text for Eikon: ID:nGNE2f3wSf
Further company coverage: OBSN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary